How glucagon-like peptide 1 receptor agonists work
In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bioscientifica
2021-07-01
|
| Series: | Endocrine Connections |
| Subjects: | |
| Online Access: | https://ec.bioscientifica.com/view/journals/ec/10/7/EC-21-0130.xml |
| _version_ | 1819151662288207872 |
|---|---|
| author | Christine Rode Andreasen Andreas Andersen Filip Krag Knop Tina Vilsbøll |
| author_facet | Christine Rode Andreasen Andreas Andersen Filip Krag Knop Tina Vilsbøll |
| author_sort | Christine Rode Andreasen |
| collection | DOAJ |
| description | In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk and renal complications in high-risk individuals with T2D. These findings have changed guidelines on T2D management over th e last years, and GLP-1RAs are now widely used in overweight patients with T2D as well as in patients with T2D and cardiovascular disease regardless of glycaemic control. The currently available GLP-1RAs have different pharmacokinetic profiles and differ in the ir ability to improve glycaemia, reduce body weight and in their cardio- and renal protective potentials. Understanding how these agents work, including insights into th eir pleiotropic effects on T2D pathophysiology, may improve their clinical utilisation and be useful for exploring other indications such as non-alcoholic steatohepatitis and neurodegenerative disorders. In this review, we provide an overview of approved GLP-1RAs, th eir clinical effects and mode of action, and we offer insights into the potential of GLP- 1RAs for other indications than T2D. Finally, we will discuss the emerging data and therapeutic potential of using GLP-1RAs in combinations with other receptor agonists. |
| first_indexed | 2024-12-22T14:36:57Z |
| format | Article |
| id | doaj.art-bc373fa183bb41c4bf117d99ac42b5be |
| institution | Directory Open Access Journal |
| issn | 2049-3614 2049-3614 |
| language | English |
| last_indexed | 2024-12-22T14:36:57Z |
| publishDate | 2021-07-01 |
| publisher | Bioscientifica |
| record_format | Article |
| series | Endocrine Connections |
| spelling | doaj.art-bc373fa183bb41c4bf117d99ac42b5be2022-12-21T18:22:38ZengBioscientificaEndocrine Connections2049-36142049-36142021-07-01107R200R212https://doi.org/10.1530/EC-21-0130How glucagon-like peptide 1 receptor agonists workChristine Rode Andreasen0Andreas Andersen1Filip Krag Knop2Tina Vilsbøll3Steno Diabetes Center Copenhagen, Gentofte, Denmark; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, DenmarkSteno Diabetes Center Copenhagen, Gentofte, Denmark; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, DenmarkSteno Diabetes Center Copenhagen, Gentofte, Denmark; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSteno Diabetes Center Copenhagen, Gentofte, Denmark; Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk and renal complications in high-risk individuals with T2D. These findings have changed guidelines on T2D management over th e last years, and GLP-1RAs are now widely used in overweight patients with T2D as well as in patients with T2D and cardiovascular disease regardless of glycaemic control. The currently available GLP-1RAs have different pharmacokinetic profiles and differ in the ir ability to improve glycaemia, reduce body weight and in their cardio- and renal protective potentials. Understanding how these agents work, including insights into th eir pleiotropic effects on T2D pathophysiology, may improve their clinical utilisation and be useful for exploring other indications such as non-alcoholic steatohepatitis and neurodegenerative disorders. In this review, we provide an overview of approved GLP-1RAs, th eir clinical effects and mode of action, and we offer insights into the potential of GLP- 1RAs for other indications than T2D. Finally, we will discuss the emerging data and therapeutic potential of using GLP-1RAs in combinations with other receptor agonists.https://ec.bioscientifica.com/view/journals/ec/10/7/EC-21-0130.xmldiabetescardiovascularmetabolisminflammationobesity |
| spellingShingle | Christine Rode Andreasen Andreas Andersen Filip Krag Knop Tina Vilsbøll How glucagon-like peptide 1 receptor agonists work Endocrine Connections diabetes cardiovascular metabolism inflammation obesity |
| title | How glucagon-like peptide 1 receptor agonists work |
| title_full | How glucagon-like peptide 1 receptor agonists work |
| title_fullStr | How glucagon-like peptide 1 receptor agonists work |
| title_full_unstemmed | How glucagon-like peptide 1 receptor agonists work |
| title_short | How glucagon-like peptide 1 receptor agonists work |
| title_sort | how glucagon like peptide 1 receptor agonists work |
| topic | diabetes cardiovascular metabolism inflammation obesity |
| url | https://ec.bioscientifica.com/view/journals/ec/10/7/EC-21-0130.xml |
| work_keys_str_mv | AT christinerodeandreasen howglucagonlikepeptide1receptoragonistswork AT andreasandersen howglucagonlikepeptide1receptoragonistswork AT filipkragknop howglucagonlikepeptide1receptoragonistswork AT tinavilsbøll howglucagonlikepeptide1receptoragonistswork |